Follow-On Biologics Legislation Faces Tough Road Ahead; Momentum Stalled

Prospects for enactment of follow-on biologics legislation appear limited in the near term, according to Capitol Hill players in the debate

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet